ProfileGDS5678 / 1422571_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 97% 96% 97% 95% 96% 95% 97% 95% 93% 95% 94% 94% 96% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.1919497
GSM967853U87-EV human glioblastoma xenograft - Control 28.8004296
GSM967854U87-EV human glioblastoma xenograft - Control 39.3865197
GSM967855U87-EV human glioblastoma xenograft - Control 48.8212695
GSM967856U87-EV human glioblastoma xenograft - Control 59.1531896
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.252595
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.1688397
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.2697595
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9330893
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.3833795
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.1133294
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.3341194
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.960896
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.4086995